Opinion
Video
Daniel Bowles, MD, discusses the toxicity profiles and adverse reactions associated with frontline and second-line treatments for differentiated thyroid cancer (DTC).
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC